18 december 2020 USA
Endocrine News: Potential Type 1 Diabetes Vaccine Shows Promise
Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum — an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant effect in genetically defined subgroups of individuals with the disease. Diamyd Medical is supporting the trials and developing the drug candidate as Diamyd®.
Read the article here
Information som presenteras här är inte pressmeddelanden och kan innehålla utdrag ur och länkar till externt publicerat innehåll. Diamyd Medical ansvarar inte för externt publicerat innehåll.